PAVmed (PAVM) Stock: Buy, Sell, or Hold?
PAVM - PAVmed Inc. Common Stock
$2.87
0.17 (6.30%)
▲
5d:
-25.36%
30d:
-46.36%
90d:
-46.05%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When PAVM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PAVM is down 25.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PAVM is down 25.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PAVM is currently trading at $2.87, which is considered oversold relative to its 30-day fair value range of $3.65 to $5.05.
Technical Outlook: Technically, PAVM is in a downtrend. Immediate support is located at $2.61, while resistance sits at $4.33. The stock is showing strong short-term momentum, up 6.3% recently.
Market Sentiment: PAVM scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $36.50 (+1171.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PAVM is in a downtrend. Immediate support is located at $2.61, while resistance sits at $4.33. The stock is showing strong short-term momentum, up 6.3% recently.
Market Sentiment: PAVM scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $36.50 (+1171.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.65 -
$5.05
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.3%)
- BULLISH: Trading 1171.8% below Wall St target ($36.50)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.65 -
$5.05
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.61
Resistance Level
$4.33
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.21
Wall Street Target
$36.50
(+1171.8%)
Revenue Growth (YoY)
450.0%
Share & Embed Analysis
Last updated: October 02, 2026 11:55 PM ET
Data refreshes hourly during market hours. Next update: 12:55 AM
Data refreshes hourly during market hours. Next update: 12:55 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PAVM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$369 | 69 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 47 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 64 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 58 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 38 SELL |
